The combination of nivolumab plus ipilimumab was at least as effective as chemotherapy in front-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and brain metastases at baseline, according to the results of a post hoc analysis from part 1 of the phase III CheckMate 227 trial, presented during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
Circulating tumor DNA (ctDNA) clearance of EGFR mutation—that is, detectable mutation at baseline that became undetectable or dropped below a predetermined threshold—appears to be predictive of extended progression-free survival for patients with EGFR-mutant, MET-amplified NSCLC with detectable ctDNA at baseline, according to an analysis of the phase I TATTON study presented at the 2020 AACR Virtual Annual Meeting II.
Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to this type of therapy is an important area of research.
For people with cancer who have a mental health disorder, getting mental health treatment may help them live longer, a new study published by Berchuck et al in JAMA Oncology suggests.
Lung cancer in nonsmokers is a diverse and distinct disease from lung cancer in smokers and is likely to respond differently to targeted treatments, according to results from a new study published by Chen et al in the journal Cell.